Trial Profile

SELECT - Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Semaglutide (Primary)
Indications Cardiovascular disorders; Myocardial infarction; Obesity; Stroke
Focus Registrational; Therapeutic Use
Acronyms SELECT
Sponsors Novo Nordisk

22 Dec 2025 According to Novo Nordisk media release, based on the OASIS trial programme and the SELECT trial ,the US Food and Drug Administration (FDA) has approved the Wegovy pill to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events.
20 Aug 2025 According to Novo Nordisk media release, the company announced that data from this study will be presented at the European Society of Cardiology (ESC) Congress 2025 from 29 August to 1 September in Madrid, Spain.
06 May 2025 According to a Novo Nordisk media release, data form this trial will be presented at the ECO 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com